4.6 Article

Transglutaminases and Disease: Lessons From Genetically Engineered Mouse Models and Inherited Disorders

Journal

PHYSIOLOGICAL REVIEWS
Volume 89, Issue 3, Pages 991-1023

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physrev.00044.2008

Keywords

-

Categories

Funding

  1. National Health and Medical Research Council [459406, 526622, 568753]
  2. Australian Research Council [DP0665422]
  3. Australian Research Council [DP0665422] Funding Source: Australian Research Council

Ask authors/readers for more resources

The human transglutaminase (TG) family consists of a structural protein, protein 4.2, that lacks catalytic activity, and eight zymogens/enzymes, designated factor XIII-A (FXIII-A) and TG1-7, that catalyze three types of posttranslational modification reactions: transamidation, esterification, and hydrolysis. These reactions are essential for biological processes such as blood coagulation, skin barrier formation, and extracellular matrix assembly but can also contribute to the pathophysiology of various inflammatory, autoimmune, and degenerative conditions. Some members of the TG family, for example, TG2, can participate in biological processes through actions unrelated to transamidase catalytic activity. We present here a comprehensive review of recent insights into the physiology and pathophysiology of TG family members that have come from studies of genetically engineered mouse models and/or inherited disorders. The review focuses on FXIII-A, TG1, TG2, TG5, and protein 4.2, as mice deficient in TG3, TG4, TG6, or TG7 have not yet been reported, nor have mutations in these proteins been linked to human disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available